CN115006494B - Inula flower composite anti-alcohol composition with pulse-displaying function, anti-alcohol and liver-protecting preparation and application thereof - Google Patents
Inula flower composite anti-alcohol composition with pulse-displaying function, anti-alcohol and liver-protecting preparation and application thereof Download PDFInfo
- Publication number
- CN115006494B CN115006494B CN202210029968.1A CN202210029968A CN115006494B CN 115006494 B CN115006494 B CN 115006494B CN 202210029968 A CN202210029968 A CN 202210029968A CN 115006494 B CN115006494 B CN 115006494B
- Authority
- CN
- China
- Prior art keywords
- extract
- inula flower
- extraction
- liver
- inula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000132446 Inula Species 0.000 title claims abstract description 95
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 239000002131 composite material Substances 0.000 title claims abstract description 19
- 230000002075 anti-alcohol Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 117
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 46
- 244000130270 Fagopyrum tataricum Species 0.000 claims abstract description 35
- 235000014693 Fagopyrum tataricum Nutrition 0.000 claims abstract description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000011161 development Methods 0.000 claims abstract description 12
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 5
- 238000000605 extraction Methods 0.000 claims description 30
- 210000004185 liver Anatomy 0.000 claims description 30
- 241000305491 Gastrodia elata Species 0.000 claims description 25
- 208000007848 Alcoholism Diseases 0.000 claims description 17
- 201000007930 alcohol dependence Diseases 0.000 claims description 17
- 241000208689 Eucommia ulmoides Species 0.000 claims description 16
- 241000208688 Eucommia Species 0.000 claims description 12
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- 206010019133 Hangover Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 241000253121 Inula britannica Species 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 210000003462 vein Anatomy 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000006189 buccal tablet Substances 0.000 abstract description 32
- 229940046011 buccal tablet Drugs 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 19
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 abstract description 12
- 206010016262 Fatty liver alcoholic Diseases 0.000 abstract description 12
- 208000026594 alcoholic fatty liver disease Diseases 0.000 abstract description 12
- 208000010706 fatty liver disease Diseases 0.000 abstract description 12
- 206010067125 Liver injury Diseases 0.000 abstract description 9
- 230000001476 alcoholic effect Effects 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 9
- 231100000753 hepatic injury Toxicity 0.000 abstract description 9
- 230000001154 acute effect Effects 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 4
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 30
- 210000005228 liver tissue Anatomy 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 22
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 13
- 102000016938 Catalase Human genes 0.000 description 12
- 108010053835 Catalase Proteins 0.000 description 12
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 11
- 229940118019 malondialdehyde Drugs 0.000 description 11
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 10
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 8
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 7
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 239000007937 lozenge Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 3
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 3
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 3
- HTPVUEJWIFHSCK-UHFFFAOYSA-N Isobuttersaeure-thymylester Natural products CC(C)C(=O)OC1=CC(C)=CC=C1C(C)C HTPVUEJWIFHSCK-UHFFFAOYSA-N 0.000 description 3
- 102000023984 PPAR alpha Human genes 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 108010063907 Glutathione Reductase Proteins 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 231100000334 hepatotoxic Toxicity 0.000 description 2
- 230000003082 hepatotoxic effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000305492 Gastrodia Species 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- -1 p-AMPK Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pulse-displaying inula flower composite anti-alcohol composition, an anti-alcohol and liver-protecting preparation and application thereof, and belongs to the technical field of food or medicine. The anti-alcohol composition contains the following extract components: 10-50 parts of inula flower extract, 1-10 parts of tartary buckwheat extract, 1-10 parts of folium cortex eucommiae extract and 1-20 parts of rhizoma gastrodiae extract, wherein the inula flower extract is a water extract, and the tartary buckwheat extract, the folium cortex eucommiae extract and the rhizoma gastrodiae extract are all ethanol extracts. The inula flower composite anti-alcoholic buccal tablet has excellent effect of treating alcoholic fat and alcoholic liver injury caused by acute alcohol intake; therefore, the inula flower composite alcohol effect relieving buccal tablet has better development and utilization prospects in the aspects of medicines or functional foods for preventing and assisting in treating alcoholic fatty liver and alcoholic liver injury.
Description
Technical Field
The invention relates to a pulse-developing inula flower composite anti-alcohol composition, an anti-alcohol and liver-protecting preparation and application thereof, and belongs to the technical field of food or medicine.
Background
Since ancient times, chinese wine culture has been a vital part of life, most people generally believe that a small amount of drinking is beneficial to health, and excessive drinking is the main factor leading to death. Statistically, in the asia-pacific region, about 30 million people die each year from alcohol-drinking related diseases, and the incidence and mortality of Alcoholic Liver Disease (ALD) caused by liver being the first and most damaged tissue as the liver is the key site for alcohol metabolism. At present, the pathogenesis of alcoholic liver disease is more complex, and the pathogenesis is probably caused by the cross action of various driving factors such as cell injury, oxidative stress, flora imbalance and the like. In recent years, although research approaches for nutrition therapy, drug therapy, liver transplantation therapy and the like for alcoholic liver diseases have been advanced, effective treatment methods for patients with final stage alcoholic liver disease are still few. Therefore, alcoholic fatty liver is an early stage of alcoholic liver disease, and is also a reversible stage in the occurrence and development of alcoholic liver disease, and is an important stage for treating and relieving alcoholic liver disease.
There is no effective treatment for alcoholic liver disease, and so far, no satisfactory drug for intervention and treatment of ALD has been found. Alcohol withdrawal is considered the most effective method clinically, however, under unavoidable circumstances, the use of Corticosteroids (corticosteroides) is recommended for the treatment of severe alcoholic hepatitis. However, these drugs have significant side effects that have stimulated a need for safe and effective drugs for the treatment of alcoholic liver disease. The method is an important direction for searching substances which are safe and have good intervention effect on alcoholic liver diseases from the traditional medicinal and edible resources in China.
Inula flower with obvious pulse, also known as Xiaoheiyao, also called Yunwailing, weilingcao and the like, is mainly distributed in northern Yunnan, southwest Sichuan, northern Guizhou and Western Guangxi, is a common national medicine in Guizhou province and the like in Yunnan, and is mainly used for treating symptoms such as cough, traumatic injury, rheumatic ostealgia, dyspepsia, neurasthenia and the like. In 2010, inula flower with pulse-appearing function was approved as a new food material by the ministry of health. Research shows that the inula flower extract for pulse development has good antioxidant effect. However, the reports on the effect of inula nervosa on relieving alcoholic liver diseases do not exist at present.
Disclosure of Invention
In view of the above technical problems, a first object of the present invention is to provide a inula flower composite anti-hangover composition, which contains the following extract components: the composition comprises an inula flower extract, a tartary buckwheat extract, an eucommia ulmoides leaf extract and a gastrodia elata extract, wherein the inula flower extract, the tartary buckwheat extract, the eucommia ulmoides leaf extract and the gastrodia elata extract are prepared from the following components in parts by weight: 10 to 50 parts by weight of inula flower extract, 1 to 10 parts by weight of tartary buckwheat extract, 1 to 10 parts by weight of eucommia ulmoides leaf extract and 1 to 20 parts by weight of gastrodia elata extract, wherein the parts by weight of the extracts refer to dry weight.
Preferably, the inula flower extract for pulse development is a water extract, and the tartary buckwheat extract, the eucommia ulmoides leaf extract and the gastrodia elata extract are all ethanol extracts.
Preferably, the raw material extract components are prepared by independently extracting raw materials or extracting the inula flower with water, mixing the inula flower with the tartary buckwheat, the eucommia leaves and the gastrodia elata, and then adding ethanol for extraction.
Preferably, the specific process of separately extracting the raw materials is as follows:
the extraction process of the inula flower water extract for pulse development: crushing rhizomes or petals of inula japonica linn to 0.1-50mm, adding water according to the weight-volume ratio of the petals or the rhizomes to the aqueous solution of 1: 1-50, carrying out ultrasonic stirring extraction, centrifuging, collecting supernatant, concentrating, and freeze-drying to obtain inula japonica linn water extract, wherein the ultrasonic frequency of ultrasonic stirring extraction is 20kHz, the extraction time is 1-5h, and the extraction temperature is 30-60 ℃;
the extraction process of the ethanol extracts of the tartary buckwheat extract, the eucommia ulmoides leaf extract and the gastrodia elata extract comprises the following steps: grinding the tartary buckwheat, the eucommia leaves and the gastrodia elata into particles with the particle size of 0.1 to 50mm by a grinder; respectively adding ethanol into the pulverized tartary buckwheat, the pulverized eucommia ulmoides leaves and the pulverized gastrodia elata, performing microwave-assisted extraction, centrifuging to obtain a supernatant, concentrating, and performing freeze drying to obtain each extract, wherein the volume ratio of the weight of each tartary buckwheat, the weight of each eucommia ulmoides leaf to the volume of the ethanol is 2 to 5; the extraction time of microwave-assisted extraction is 0.5 to 2h, the extraction temperature is 20 to 50 ℃, and the microwave extraction power is 200 to 500W.
The process of the mixed extraction of the extract comprises the following steps:
(1) Crushing rhizomes or petals of inula flower with vein appearance to 0.1 to 50mm, adding water according to the weight volume ratio of the petals or the rhizomes to the aqueous solution of 1: 1 to 50, carrying out ultrasonic stirring extraction, centrifuging, collecting supernate, and concentrating to obtain an inula flower water extract with vein appearance, wherein the ultrasonic frequency of ultrasonic stirring extraction is 20kHz, the extraction time is 1 to 5 hours, and the extraction temperature is 30 to 60 ℃;
(2) Grinding the tartary buckwheat, the eucommia leaves and the gastrodia elata into particles with the particle size of 0.1 to 50mm by a grinder; taking the water extract of the inula flower with pulse taking prepared in the step (1), an ethanol solution, the pulverized tartary buckwheat, folium cortex eucommiae and rhizoma gastrodiae, uniformly mixing, performing microwave-assisted extraction, centrifuging, taking supernate, and performing freeze drying to obtain a mixed extract, wherein the ratio of the weight of each of the tartary buckwheat, the folium cortex eucommiae and the rhizoma gastrodiae to the volume of each of the inula flower water extract and the ethanol is 2 to 5; the extraction time of microwave-assisted extraction is 0.5 to 2h, the extraction temperature is 20 to 50 ℃, and the microwave extraction power is 200 to 500W.
The invention also aims to provide an anti-alcoholism and liver-protecting preparation, which comprises the anti-alcoholism composition; the preparation form of the preparation for relieving alcoholism and protecting liver is oral liquid, capsules, tablets or pills.
The anti-alcoholism composition is directly combined with conventional auxiliary materials to be prepared into oral liquid or gel by a conventional method; the anti-alcoholism composition is freeze-dried into powder, then is combined with conventional auxiliary materials to be prepared into capsules, tablets or pills according to a conventional method.
The inula flower extract for pulse display refers to a water extract of rhizome and/or petal powder of inula flower for pulse display.
The third purpose of the invention is to provide the application of the hangover alleviating composition in liver-protecting functional foods, health-care products and medicines.
The records of the application of the inula flower for pulse manifestation are recorded in Yunnan materia medica, and the modern medical research proves that: thymol and thymyl isobutyrate are main drug effect components in the inula flower for pulse development, and the inula flower for pulse development has the effects of relieving asthma, eliminating phlegm, diminishing inflammation, inhibiting bacteria and the like; the eucommia ulmoides leaves are slightly pungent and warm, enter liver and kidney channels, have the efficacy of tonifying liver and kidney and are mainly used for treating symptoms such as liver and kidney, asthma, fatigue and the like according to records in pharmacopoeia of the people's republic of China; as recorded in pharmacopoeia of the people's republic of China, gastrodia elata has the effects of calming wind and relieving spasm, calming liver-yang, dispelling wind and dredging collaterals. Mainly treats abnormal liver diseases; as recorded in Ben Cao gang mu, tartary buckwheat has the effects of relieving cough, relieving asthma, resisting inflammation, etc. The composition is based on the characteristics of several plants, and uses folium cortex eucommiae and rhizoma gastrodiae to protect the liver, develop pulse and inula flower and tartary buckwheat to relieve inflammation, so that the composition interacts with each other and improves liver inflammation and intestinal inflammation caused by alcohol intake.
Compared with the prior art, the invention has the following advantages:
experiments show that the inula flower composite anti-alcoholic buccal tablet can still effectively improve liver fat accumulation, liver oxidative stress and development inflammatory reaction of chronic alcoholic fatty liver model rats under lower concentration, thereby playing a role in improving alcoholic fatty liver caused by long-term alcohol intake.
The inula flower is approved as a new food raw material by the ministry of health in 2010, the safety of the inula flower is guaranteed, and the inula flower has smaller side effect than a commercially available drug for treating alcoholic liver disease.
Drawings
FIG. 1 shows the regulation of triglyceride and total cholesterol content in liver of rat with chronic alcoholic fatty liver by the inula flower buccal tablet.
FIG. 2 is a section of liver tissue H & E stained by inula flower sobering-up tablet for chronic alcoholic fatty liver rat.
FIG. 3 shows the regulation of the content of hepatotoxic substances in the serum of a chronic alcoholic fatty liver rat by the pulse-developing inula flower alcohol-relieving buccal tablet.
FIG. 4 shows the expression of liver tissue protein of rats with chronic alcoholic fatty liver caused by the Inula japonica anti-hangover tablet.
Fig. 5 shows the regulation of triglyceride and total cholesterol content in liver of mice with acute alcoholic liver injury by inula flower sobering-up buccal tablet.
FIG. 6 is a section of H & E stained liver tissue of mice with acute alcoholic liver injury by inula flower sobering-up buccal tablets.
Fig. 7 shows the regulation of the content of hepatotoxic substances in the serum of mice with acute alcoholic liver injury by the inula flower sobering-up tablet.
Detailed Description
The technical solutions of the present invention are described below clearly and completely with reference to specific embodiments, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
A composite inula flower anti-alcoholism composition with pulse-displaying function contains the following extract components: the composition comprises an extract of inula flower (petal), an extract of tartary buckwheat, an extract of eucommia leaves and an extract of gastrodia elata, wherein the extract comprises the following components in parts by weight: 10 parts of inula flower extract, 1 part of tartary buckwheat extract, 1 part of eucommia ulmoides leaf extract and 1 part of gastrodia elata extract.
Example 2
A composite inula flower anti-alcoholism composition with pulse-displaying function contains the following extract components: the composition comprises an extract of inula flower (petal), an extract of tartary buckwheat, an extract of eucommia leaves and an extract of gastrodia elata, wherein the extract comprises the following components in parts by weight: 50 parts of inula flower extract, 10 parts of tartary buckwheat extract, 10 parts of eucommia ulmoides leaf extract and 20 parts of gastrodia elata extract.
Example 3
A composite inula flower anti-alcoholism composition with pulse-displaying function contains the following extract components: the composition comprises an extract of inula flower (rhizome), an extract of tartary buckwheat, an extract of eucommia leaves and an extract of gastrodia elata, wherein the extract comprises the following components in parts by weight: 25 parts of inula flower extract, 2 parts of tartary buckwheat extract, 2 parts of eucommia ulmoides leaf extract and 2 parts of gastrodia elata extract.
Example 4
A composite inula flower anti-alcoholism composition with pulse-displaying function contains the following extract components: the composition comprises an extract (petal and rhizome) of the inula flower for pulse development, an extract of tartary buckwheat, an extract of eucommia leaves and an extract of gastrodia elata, wherein the extract comprises the following components in parts by weight: 25 parts of inula flower extract for pulse development, 8 parts of tartary buckwheat extract, 8 parts of eucommia leaf extract and 15 parts of gastrodia tuber extract.
The embodiment of the invention takes tablets as an example for illustration, and the specific preparation process is as follows:
(1) Pulverizing stems and petals of Inula nervosa Vahl of Kunming city of Yunnan province by a pulverizer to particle size of 10mm to obtain samples of stems and petals of Inula nervosa Vahl of Yunnan province; respectively weighing samples of the rhizome and the petal of the inula flower, extracting for 5h by ultrasonic wave (20 kHz) at 30 ℃ with aqueous solution according to the proportion of material to liquid of 1kg and 10L, centrifuging for 10min at 8000r/min, taking supernatant, and performing rotary evaporation and concentration at 45 ℃ to obtain a water extract of the rhizome and the petal of the inula flower.
(2) Mixing the root-stem water extract and the petal water extract of the pulse-appearing inula flower respectively with the tartary buckwheat, the eucommia leaves, the gastrodia elata and the ethanol solution which are crushed to be 10nm in particle size by a crusher according to a proportion of 1L.
(3) Mixing 2g magnesium stearate with 30g inula flower petal composite extract or 30g inula flower rhizome composite extract, tabletting and packaging; the inula flower petal sobering-up buccal tablets with the diameter of 6.4 mm and the weight of 635 mg and the inula flower rhizome sobering-up buccal tablets with the diameter of 7.6 mm and the weight of 864 mg are respectively obtained.
The effects of the four inula flower-based anti-alcohol lozenges prepared in examples 1 to 4 are further explained below as examples.
Verification experiment 1
Relieving effect of inula japonica rhizome composite extract on chronic alcoholic fatty liver
1. Grouping
After being fed by adaptive feeding for 1 week by 60 male SD rats (provided by department of animal sciences of Kunming medical university) of 7 weeks, the SD rats were randomly divided into 6 groups, 10 rats in each group were respectively a normal group (Control), a model group (AFLD), an intervention group 1 (alcohol lozenge obtained in example 1), an intervention group 2 (alcohol lozenge obtained in example 2), an intervention group 3 (alcohol lozenge obtained in example 3), and an intervention group 4 (alcohol lozenge obtained in example 4); the Inulae flos anti-hangover buccal tablet with pulse-taking effect is added into the dried group according to the proportion of 600 mg/kg.
2. Modeling
Except that the normal group of mice can be freely drunk by mineral water every day, the mice are gavaged for 1 time with 20 percent alcohol every day in the first week, the gavage volume is 5ml/kg, and the mice are fully gavaged with 56 percent alcohol in the rest time; after the alcohol is filled into the stomachs, the extracts corresponding to the experimental groups are filled into the stomachs respectively, and the volume of the filled stomachs is 5ml/kg; during this period the normal group was gavaged with the corresponding volume of distilled water for 12 weeks; during the molding period, the mental behavior state of the rat is observed three times in the morning, the evening and every day to see whether the mental behavior state is normal or not and to make a record in time, and the rat is weighed and recorded every 3 days. Adding water and feed once every two days, recording the residual amount of the water and the feed before each addition, and calculating the intake amount of the feed and the water; after fasting for 12 hours after the last 1 gavage, the rats were sacrificed and blood was collected and rat livers were separated using centrifuge tubes containing anticoagulants.
3. Determination of liver triglyceride and total cholesterol content
Rinsing the picked rat liver with normal saline, sucking water with filter paper, cutting part of tissue, homogenizing, and determining Triglyceride (TG) and Total Cholesterol (TC) contents with kit; as shown in FIG. 1, the liver tissues of mice in the AFLD group showed significantly increased TC and TG contents compared to those in the normal group. The TC and TG contents in the liver tissues of rats in the inula nervosa rhizome alcohol-relieving buccal tablet intervention group and the inula nervosa petal alcohol-relieving buccal tablet intervention group are obviously reduced; therefore, the inula flower rhizome anti-alcoholism buccal tablet and the inula flower petal anti-alcoholism buccal tablet for treating and relieving the symptoms of alcoholic fatty liver are treated.
4. Morphological observation of pathological tissues
The rats were sacrificed at 12 weeks, blood was collected, and livers were removed; fixing the liver with 10% formalin, and performing histopathological morphological observation after HE staining; the results are shown in fig. 2, compared with the control group, small and dense lipid droplets appear in liver cells of rats in the AFLD group, inflammatory cell infiltration occurs, and fatty degeneration occurs in liver cells; the round lipid droplet cavity and inflammatory cell infiltration in the pulse-displaying inula flower rhizome anti-alcoholism buccal tablet intervention group are obviously less than those in the AFLD group; after the pulse-appearing inula flower alcohol-relieving buccal tablet is dried, the liver fat accumulation condition caused by long-term alcohol intake of rats is obviously improved.
5. Serum biochemical index level detection
Centrifuging the collected blood sample by a low-speed centrifuge at 3500g for 15min, and collecting supernatant with aspartate Aminotransferase (AST) and alanine Aminotransferase (ALT) levels in plasma; the results are shown in fig. 3, the level of AST and ALT in the serum of the rat in the AFLD group is obviously higher than that in the control group; the AST and ALT levels in the serum of the intervention groups 1, 2, 3 and 4 given 600mg/kg pulse-developing inula flower anti-alcoholism tablets are obviously reduced.
6. Liver biochemical index level detection
Taking part of rat liver tissue, adding normal saline, homogenizing, centrifuging, and taking supernatant. Determining the levels of Malondialdehyde (MDA), catalase (CAT), alcohol Dehydrogenase (ADH) and glutathione reductase (GSH-px) in the supernatant of the colon homogenate using the kit; the results are shown in Table 1, the levels of inflammatory factors IL-6 and TNF-alpha in liver tissues of rats in the AFLD group are obviously increased compared with those in the control group; the levels of inflammatory factors IL-6 and TNF-alpha in liver tissues of mice in the intervention groups 1, 2, 3 and 4, which are given 600mg/kg pulse-developing inula flower alcohol-dispelling buccal tablets, are obviously reduced compared with those of rats in the AFLD group.
TABLE 1 influence of pulse-developing flos Inulae lozenge for relieving alcoholic intoxication on liver tissue inflammatory factor of rat with alcoholic fatty liver
The levels of Malondialdehyde (MDA), glutathione peroxidase activity (GSH-px), alcohol Dehydrogenase (ADH) and Catalase (CAT) in rat liver tissue are shown in Table 2; MDA and ADH levels in liver tissues of rats in the AFLD group are obviously increased compared with those in a control group, and GSH-px and CAT levels are obviously reduced; the MDA and ADH levels in the liver tissues of mice of the intervention groups 1, 2, 3 and 4 given 600mg/kg pulse-appearing inula flower alcohol-dispelling tablets are obviously reduced, and the GSH-px and CAT levels are obviously increased compared with those of the AFLD group.
Table 2. Influence of Inula nervosa flower alcohol effect relieving buccal tablets on oxidative stress of liver tissues of rats with alcoholic fatty liver
Note: significant differences between data of different superscript letters in the same column (p < 0.05)
6. Protein expression assay
Weighing a certain amount of liver tissue, extracting protein of the liver tissue, and detecting the expression of AMPK, p-AMPK, PPAR-alpha and CYP2E1 protein in colon tissue by using Westernblot. The results are shown in FIG. 4, the relative expression levels of AMPK, p-AMPK and PPAR-alpha protein in liver tissues of rats in the AFLD group are obviously reduced compared with those in the normal group; the relative expression quantity of the CYP2E1 protein is obviously increased. After the intervention groups 1, 2, 3 and 4 are given 600mg/kg of the inula flower anti-alcoholism buccal tablets, compared with the AFLD group, the relative expression quantity of AMPK, p-AMPK and PPAR-alpha protein is obviously increased after 12 weeks; the relative expression level of CYP2E1 protein is obviously reduced, and the liver fat accumulation of rats and the liver injury caused by alcohol are obviously improved.
Verification experiment 2
Therapeutic effect of inula flower extract on acute alcoholic liver injury
1. Grouping and modeling
After all mice are fed adaptively for one week, the corresponding extracts of the intervention groups are respectively gavaged, and the gavage volume is 5ml/kg. During this period, the control group was gavaged with a corresponding volume of distilled water for three weeks. During the feeding period, the body weight of the mice was weighed and recorded every three days, and the gastric perfusion amount was adjusted. After 12 hours of last intragastric administration, 12 mL/kg.weight of distilled water is given as a control, and 12 mL/kg.weight of 50% ethanol solution is administered for intragastric administration for the other groups; after fasting for 12 hours after the last 1 gavage, the mice were sacrificed and blood was collected and mouse livers were separated using centrifuge tubes containing anticoagulants.
2. Determination of liver triglyceride and total cholesterol content
The extracted mouse liver was rinsed with normal saline and then dried with filter paper, and then a part of the tissue was cut and homogenized, and then the contents of Triglyceride (TG) and Total Cholesterol (TC) were measured using a kit. The results are shown in fig. 5, compared with the normal group, the contents of TC and TG in the liver tissues of the ALD group mice are obviously increased, and after the inula pulmonarius alcohol effect relieving buccal tablet is administered, the contents of TC and TG in the liver tissues of the mice are obviously reduced, which indicates that the inula pulmonarius alcohol effect relieving buccal tablet relieves the symptom of liver fat accumulation caused by acute alcohol intake.
3. Determination of liver triglyceride and total cholesterol content
After the mice are sacrificed, the collected livers are fixed by 10 percent formalin, and are subjected to pathological histomorphometry after HE staining; the results are shown in fig. 6, compared with the control group, small and dense lipid droplets appear in the liver cells of the ALD group mice, inflammatory cell infiltration occurs, and the liver cells are subjected to steatosis; after the pulse-developing inula flower alcohol-relieving buccal tablet is used for treating the liver dryness, no obvious fat drop and inflammatory cell infiltration condition can be seen in the liver tissue of a mouse, and the liver fat accumulation and liver cell injury condition caused by acute alcohol intake of the mouse can be obviously improved.
4. Serum biochemical index level detection
Centrifuging the collected blood sample by a low-speed centrifuge at 3500g for 15min, and taking supernatant fluid and AST and ALT levels in plasma; the results are shown in FIG. 7, and the AST and ALT levels in the blood serum of the mice in the ALD group are obviously higher than those in the control group; after 400mg/kg and 800 mg/kg of the pulse-appearing inula flower rhizome anti-inebriation buccal tablets are given, the AST and ALT levels in serum are obviously reduced.
5. Liver biochemical index level detection
Taking part of mouse liver tissue, adding normal saline, homogenizing, centrifuging, and taking supernatant. The kit was used to determine the levels of Malondialdehyde (MDA), catalase (CAT), alcohol Dehydrogenase (ADH) and glutathione reductase (GSH-px) in the colon homogenate supernatant. The results are shown in Table 3, the levels of inflammatory factors IL-6 and TNF-alpha in liver tissues of rats in the AFLD group are obviously increased compared with the control group; the levels of inflammatory factors IL-6 and TNF-alpha in liver tissues of mice in the intervention groups 1, 2, 3 and 4 given 600mg/kg pulse-appearing inula flower alcohol effect relieving buccal tablets are obviously reduced compared with those of rats in the AFLD group.
Table 3. Influence of inula flower anti-alcoholic buccal tablets on liver tissue inflammatory factors of mice with alcoholic liver injury
The levels of Malondialdehyde (MDA), glutathione peroxidase activity (GSH-px), alcohol Dehydrogenase (ADH), and Catalase (CAT) in mouse liver tissue are shown in Table 4. Compared with a control group, the level of inflammatory factor MDA in liver tissue of rats in the AFLD group is obviously increased, and the levels of GSH-px and CAT are obviously reduced; after 600mg/kg of the inula flower anti-alcohol buccal tablets are taken, the levels of SH-px and CAT in liver tissues of mice in the intervention group 1, the intervention group 2, the intervention group 3 and the intervention group 4 are obviously increased compared with those in the AFLD group.
Table 4. Influence of inula flower anti-alcoholic buccal tablets on oxidative stress of liver tissues of mice with alcoholic liver injury
Note: there were significant differences (p < 0.05) between the data for different superscript letters in the same column.
Claims (6)
1. A pulse-developing inula flower composite anti-alcohol composition is characterized in that: the anti-alcoholism composition contains the following extract components: the composition comprises an inula flower extract, a tartary buckwheat extract, an eucommia ulmoides leaf extract and a gastrodia elata extract, wherein the weight parts of the components are as follows: 10 to 50 parts by weight of inula flower extract, 1 to 10 parts by weight of tartary buckwheat extract, 1 to 10 parts by weight of eucommia ulmoides leaf extract and 1 to 20 parts by weight of gastrodia elata extract.
2. The pulse-developing inula flower composite anti-alcohol composition according to claim 1, which is characterized in that: the inula flower extract for pulse development is a water extract, and the tartary buckwheat extract, the eucommia ulmoides leaf extract and the gastrodia elata extract are all ethanol extracts.
3. The inula flower composite anti-hangover composition for improving pulse according to claim 2, wherein: the method is characterized in that the raw materials are independently extracted, and the specific process comprises the following steps:
the extraction process of the inula flower water extract for pulse development: crushing rhizomes or petals of inula flower with vein appearance to 0.1 to 50mm, adding water according to the weight volume ratio of the petals or the rhizomes to the aqueous solution of 1: 1 to 50, carrying out ultrasonic stirring extraction, centrifuging, collecting supernate, concentrating, and carrying out freeze drying to obtain an inula flower water extract with vein appearance, wherein the ultrasonic frequency of ultrasonic stirring extraction is 20kHz, the extraction time is 1 to 5 hours, and the extraction temperature is 30 to 60 ℃;
the extraction process of the ethanol extracts of the tartary buckwheat extract, the eucommia leaf extract and the gastrodia elata extract comprises the following steps: grinding the tartary buckwheat, the eucommia leaves and the gastrodia elata into particles with the particle size of 0.1 to 50mm by a grinder; respectively adding ethanol into the pulverized tartary buckwheat, the pulverized eucommia ulmoides leaves and the pulverized gastrodia elata, performing microwave-assisted extraction, centrifuging to obtain a supernatant, concentrating, and performing freeze drying to obtain each extract, wherein the volume ratio of the weight of each tartary buckwheat, the weight of each eucommia ulmoides leaf to the volume of the ethanol is 2 to 5; the extraction time of microwave-assisted extraction is 0.5 to 2h, the extraction temperature is 20 to 50 ℃, and the microwave extraction power is 200 to 500W.
4. The inula flower composite anti-hangover composition for improving pulse according to claim 2, wherein: the raw materials are mixed and extracted, and the specific process is as follows:
(1) Crushing rhizomes or petals of inula japonica linn to 0.1-50mm, adding water according to the weight-volume ratio of the petals or the rhizomes to the aqueous solution of 1: 1-50, carrying out ultrasonic stirring extraction, centrifuging, collecting supernate, and concentrating to obtain an inula japonica linn water extract, wherein the ultrasonic frequency of ultrasonic stirring extraction is 20kHz, the extraction time is 1-5h, and the extraction temperature is 30-60 ℃;
(2) Grinding the tartary buckwheat, the eucommia leaves and the gastrodia elata into particles with the particle size of 0.1 to 50mm by a grinder; taking the water extract of the inula flower with pulse taking prepared in the step (1), an ethanol solution, the pulverized tartary buckwheat, folium cortex eucommiae and rhizoma gastrodiae, uniformly mixing, performing microwave-assisted extraction, centrifuging, taking supernate, and performing freeze drying to obtain a mixed extract, wherein the ratio of the weight of each of the tartary buckwheat, the folium cortex eucommiae and the rhizoma gastrodiae to the volume of each of the inula flower water extract and the ethanol is 2 to 5; the extraction time of microwave-assisted extraction is 0.5 to 2h, the extraction temperature is 20 to 50 ℃, and the microwave extraction power is 200 to 500W.
5. An anti-hangover and liver-protecting preparation containing the inula flower composition for taking pulse according to any one of claims 1 to 4, which is characterized in that: the preparation form of the preparation for relieving alcoholism and protecting liver is oral liquid, capsules, tablets or pills.
6. The preparation of claim 5, wherein the anti-hangover composition is directly combined with conventional adjuvants and prepared into oral liquid by conventional method; the anti-alcoholism composition is freeze-dried into powder, then is combined with conventional auxiliary materials to be prepared into capsules, tablets or pills according to a conventional method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210029968.1A CN115006494B (en) | 2022-01-12 | 2022-01-12 | Inula flower composite anti-alcohol composition with pulse-displaying function, anti-alcohol and liver-protecting preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210029968.1A CN115006494B (en) | 2022-01-12 | 2022-01-12 | Inula flower composite anti-alcohol composition with pulse-displaying function, anti-alcohol and liver-protecting preparation and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115006494A CN115006494A (en) | 2022-09-06 |
| CN115006494B true CN115006494B (en) | 2023-04-11 |
Family
ID=83064798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210029968.1A Active CN115006494B (en) | 2022-01-12 | 2022-01-12 | Inula flower composite anti-alcohol composition with pulse-displaying function, anti-alcohol and liver-protecting preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115006494B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102663311B1 (en) * | 2022-12-20 | 2024-05-08 | 전북특별자치도(농업기술원) | Feed additive composition containing Gastrodia elata and manufacturing method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1507807A (en) * | 2002-12-13 | 2004-06-30 | 韩全文 | Eucommia composite multi-strain fermented functional beverage |
-
2022
- 2022-01-12 CN CN202210029968.1A patent/CN115006494B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 陆齐天等.古籍记载的单味解酒中药现代研究进展.中华中医药学刊.2017,35(第01期),100-103. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115006494A (en) | 2022-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106336445B (en) | The preparation method and application of compound 20 (R) ginseng sapoglycoside Rg 3 | |
| CN115006494B (en) | Inula flower composite anti-alcohol composition with pulse-displaying function, anti-alcohol and liver-protecting preparation and application thereof | |
| CN110893197B (en) | Panax notoginseng extract for treating gout and preparation method thereof | |
| KR100483707B1 (en) | Cartilage protective ingredients from medicinal plants and their composition | |
| CN109674848A (en) | A kind of preparation method and purposes of licorice | |
| CN111632082B (en) | American ginseng and hovenia dulcis thunb composition and application thereof in preparing medicine for preventing and treating alcoholic liver injury | |
| CN112515167A (en) | Pulse-developing inula flower composite extract and preparation method and application thereof | |
| CN110840950A (en) | Application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating non-alcoholic liver disease and/or non-alcoholic liver injury | |
| CN102579587A (en) | Traditional Chinese medicine composition for preventing and treating diabetes and complications thereof | |
| KR20220020147A (en) | Method for preparing Phellinus linteus mycelia extract or Phellinus linteus mycelia extract powder and composition for enhancing immunity comprising them as an active ingredient | |
| CN110882319A (en) | Application of thoroughfare bitter orange, thoroughfare bitter orange extract and products containing thoroughfare bitter orange extract in preventing and/or treating metabolic liver diseases | |
| KR102627108B1 (en) | Pharmaceutical composition for preventing, improving or treating nonalcoholic fatty liver comprising mixture of Acer tegmentosum Maxim extract and mushroom extract as effective material and manufacturing method for the same | |
| CN104473992B (en) | A kind of Radix Platycodonis extract and the new application in medicine and health products are prepared | |
| CN114848764B (en) | Traditional Chinese medicine compound composition for preventing and treating liver injury and preparation method and application thereof | |
| CN112494626B (en) | Tablet with protective effect on chemical liver injury and preparation method thereof | |
| CN115671219B (en) | Traditional Chinese medicine composition for treating gout and preparation method and application thereof | |
| KR102465450B1 (en) | A composition for preventing or treating alcoholic liver disease comprising an extract mixture | |
| CN114949023B (en) | New application of inula variegata extract | |
| Xu et al. | Advances in studies on bioactivity of Hovenia dulcis | |
| CN109481481B (en) | Preparation method and application of chimonanthus salicifolius total flavone extract | |
| CN117882864A (en) | Composition for preventing Alzheimer disease and preparation method and application thereof | |
| CN108126134B (en) | Traditional Chinese medicine compound composition for treating liver injury, preparation method and application thereof | |
| CN107998335B (en) | Composition for auxiliary protection of chemical liver injury, preparation method thereof and traditional Chinese medicine preparation | |
| CN114376225A (en) | Astragalus functional food for improving alcoholic liver injury | |
| CN105617024B (en) | a Chinese medicinal composition for treating psoriasis, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |